Literature DB >> 12501972

Gamma knife radiosurgery in the management of patients with acromegaly: a review.

A S Mahmoud-Ahmed1, J H Suh, M R Mayberg.   

Abstract

Although acromegaly is a rare disease, the need for an effective treatment that is able to induce biochemical cure is an extremely important issue. Unsuccessfully treated acromegaly is associated with increased morbidity and an age-corrected mortality so that early and aggressive therapy to normalize hormonal levels should be instituted at diagnosis. Ideally, the growth hormone-secreting adenoma should be completely resected, with preservation or subsequent restoration of pituitary function. Patients with recurrence or failure after surgery are treated with a second surgery, medical, radiation treatment, or combined modality treatment. Steotactic radiosurgery with gamma knife allows the delivery of focused radiation in a single session to the pituitary tumor that delivers a more biologically effective dose to the tumor than fractionated radiotherapy. Its use as a primary or adjuvant treatment for acromegalics may be more cost effective than medical treatment in these patients. Although it seems to be very effective in controlling growth and secretion of the growth hormone-secreting pituitary adenomas, there is a chance that some major risks from gamma knife radiosurgery might occur. This article will review the role that gamma knife radiosurgery might have in patients with acromegaly.

Entities:  

Mesh:

Year:  2001        PMID: 12501972     DOI: 10.1023/a:1020794329975

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  59 in total

Review 1.  Stereotactically delivered cranial radiation therapy: a ten-year experience of linac-based radiosurgery in the UK.

Authors:  E Sims; D Doughty; E Macaulay; N Royle; C Wraith; R Darlison; P N Plowman
Journal:  Clin Oncol (R Coll Radiol)       Date:  1999       Impact factor: 4.126

2.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

3.  The role of radiosurgery and particulate embolization in the treatment of dural arteriovenous fistulas.

Authors:  M J Link; R J Coffey; D A Nichols; D A Gorman
Journal:  J Neurosurg       Date:  1996-05       Impact factor: 5.115

4.  Pituitary adenomas treated by microsurgery with or without Gamma Knife surgery: experience in 122 cases.

Authors:  H K Inoue; H Kohga; M Hirato; T Sasaki; J Ishihara; T Shibazaki; C Ohye; Y Andou
Journal:  Stereotact Funct Neurosurg       Date:  1999       Impact factor: 1.875

5.  Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus.

Authors:  M Shin; H Kurita; T Sasaki; M Tago; A Morita; K Ueki; T Kirino
Journal:  J Neurosurg       Date:  2000-12       Impact factor: 5.115

6.  Radiosurgery for growth hormone-producing pituitary adenomas.

Authors:  N Zhang; L Pan; E M Wang; J Z Dai; B J Wang; P W Cai
Journal:  J Neurosurg       Date:  2000-12       Impact factor: 5.115

7.  The Mayo Clinic gamma knife experience: indications and initial results.

Authors:  B E Pollock; D A Gorman; P J Schomberg; R W Kline
Journal:  Mayo Clin Proc       Date:  1999-01       Impact factor: 7.616

8.  Gamma knife surgery in pituitary microadenomas.

Authors:  Y G Park; J W Chang; E Y Kim; S S Chung
Journal:  Yonsei Med J       Date:  1996-06       Impact factor: 2.759

9.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

10.  Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

Authors:  B Swearingen; F G Barker; L Katznelson; B M Biller; S Grinspoon; A Klibanski; N Moayeri; P M Black; N T Zervas
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

View more
  6 in total

Review 1.  Growth hormone and its disorders.

Authors:  J Ayuk; M C Sheppard
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

Review 2.  Radiotherapy and radiosurgery in acromegaly.

Authors:  Frédéric Castinetti; Isabelle Morange; Henry Dufour; Jean Regis; Thierry Brue
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 3.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006

4.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09

5.  The Impact of Insulin-Like Growth Factor Index and Biologically Effective Dose on Outcomes After Stereotactic Radiosurgery for Acromegaly: Cohort Study.

Authors:  Christopher S Graffeo; Diane Donegan; Dana Erickson; Paul D Brown; Avital Perry; Michael J Link; William F Young; Bruce E Pollock
Journal:  Neurosurgery       Date:  2020-09-01       Impact factor: 5.315

Review 6.  Acromegaly.

Authors:  Philippe Chanson; Sylvie Salenave
Journal:  Orphanet J Rare Dis       Date:  2008-06-25       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.